Capricor Therapeutics (CAPR) Profit After Tax (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Profit After Tax of -$34.5 million for Q1 2026, down 46.19% year-over-year from -$64.1 million in Q1 2025, and down 11.6% quarter-over-quarter from -$30.9 million in Q4 2025.
Capricor Therapeutics (CAPR) Profit After Tax (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$34.5 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 46.19% year-over-year to -$34.5 million; the TTM figure through Mar 2026 stood at -$116.4 million (down 118.29% YoY), while the FY2025 annual figure was -$105.8 million, down 166.63% from the prior year.
- Profit After Tax for Q1 2026 stood at -$34.5 million, down from -$30.9 million in the prior quarter.
- The five-year high for Profit After Tax was -$770053.0 in Q4 2023, with the low at -$34.5 million in Q1 2026.
- The 5-year median for Profit After Tax is -$7.8 million (2022), against an average of -$13.6 million.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax soared 90.02% in 2023, then plunged 703.3% in 2024.
- Capricor Therapeutics' Profit After Tax stood at -$7.7 million in 2022, then surged by 90.02% to -$770053.0 in 2023, then sank by 703.3% to -$6.2 million in 2024, then tumbled by 399.76% to -$30.9 million in 2025, then slipped by 11.6% to -$34.5 million in 2026.
- Business Quant data shows CAPR's Profit After Tax at -$34.5 million in Q1 2026, -$30.9 million in Q4 2025, and -$25.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | -34.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.50 Mn |
| Dec 31, 2025 | -30.91 Mn |
| Sep 30, 2025 | -25.11 Mn |
| Jun 30, 2025 | -25.91 Mn |
| Mar 31, 2025 | -23.60 Mn |
| Dec 31, 2024 | -6.19 Mn |
| Sep 30, 2024 | -12.56 Mn |
| Jun 30, 2024 | -11.00 Mn |
| Mar 31, 2024 | -9.79 Mn |
| Dec 31, 2023 | -770,053.00 |
| Sep 30, 2023 | -6.50 Mn |
| Jun 30, 2023 | -7.37 Mn |
| Mar 31, 2023 | -7.77 Mn |
| Dec 31, 2022 | -7.71 Mn |
| Sep 30, 2022 | -6.37 Mn |
| Jun 30, 2022 | -7.11 Mn |
| Mar 31, 2022 | -7.82 Mn |
| Dec 31, 2021 | -6.22 Mn |
| Sep 30, 2021 | -3.90 Mn |
| Jun 30, 2021 | -4.75 Mn |